Background: A significant proportion of stroke patients presenting with mild symptoms does not have a successful recovery, especially when a large vessel is occluded. IV thrombolysis is safe and may benefit patients presenting with mild symptoms. In this study, we tested whether endovascular therapy (ET) is superior to medical therapy in these patients. Methods: Observational, prospectively collected, multicenter study of 78 consecutive patients admitted from 2009 to 2012 within 6 h of stroke, with NIHSS ≤5 at presentation or during initial diagnostic work-up and large vessel occlusion. Data for patients undergoing ET and/or IV thrombolysis were taken from the SONIIA registry of reperfusion therapies in Catalonia, or from our local stroke registry if no reperfusion therapy was delivered. We compared risk factors, clinical course, collateral circulation, revascularization rates, hemorrhagic complications, infarct volume, and the functional outcome at 3 months of patients treated with ET and those not receiving ET. Ordinal regression was used to assess the independent effect of ET on functional outcome. Results: Baseline characteristics were similar for ET (n = 34) and medically (n = 44) treated patients, except for older age in the latter. The occlusions were located in the terminal internal carotid artery (1%), M1 segment of the middle cerebral artery (33%), M2 segment (30%), posterior circulation (31%), and 5% of the patients had tandem lesions, with no significant differences between groups. Most patients in both treatment groups had good collateral flow. The rate of successful revascularization (91.2 vs. 63.4%; p = 0.006) and the risk of symptomatic intracranial hemorrhage (11.8 vs. 0%; p = 0.033) were higher in the ET group. The NIHSS scores were similar at hospital arrival, after initial neuroimaging, and at 24 h in both treatment groups and there were no significant differences in the infarct volume in a follow-up MRI. At 3 months, 35.9% of the patients had some disability. The functional outcome was similar in both treatment groups in univariate analysis and also in models adjusted for age and initial NIHSS or for variables associated to functional outcome on univariate comparison. Conversely, IV thrombolysis was associated with significantly greater chances of full recovery after adjusting for baseline differences (OR 3.70, p = 0.015). Conclusions: One third of stroke patients with mild symptoms and large vessel occlusions do not have a successful recovery. ET is effective to recanalize the occluded vessel but increases the risk of serious bleeding significantly without improving the functional outcome, and is therefore not justified routinely in these patients.

Keywords:
Acute stroke, Ischemic stroke, Mild symptoms, Endovascular therapy, Thrombolysis, Medical treatment, Large vessel occlusion
1.
Fonarow GC, Saver JL, Smith EE, et al: Relationship of national institutes of health stroke scale to 30-day mortality in medicare beneficiaries with acute ischemic stroke. J Am Heart Assoc 2012;1:42-50.
2.
Dhamoon MS, Moon YP, Paik MC, et al: Long-term functional recovery after first ischemic stroke: the Northern Manhattan Study. Stroke 2009;40:2805-2811.
3.
Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM: Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001;56:1015-1020.
4.
Khatri P, Conaway MR, Johnston KC; Acute Stroke Accurate Prediction Study (ASAP) Investigators: Ninety-day outcome rates of a prospective cohort of consecutive patients with mild ischemic stroke. Stroke 2012;43:560-562.
5.
Leira EC, Ludwig BR, Gurol ME, Torner JC, Adams HP Jr: The types of neurological deficits might not justify withholding treatment in patients with low total National Institutes of Health Stroke Scale scores. Stroke 2012;43:782-786.
6.
Smith EE, Abdullah AR, Petkovska I, Rosenthal E, Koroshetz WJ, Schwamm LH: Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke. Stroke 2005;36:2497-2499.
7.
Nedeltchev K, Schwegler B, Haefeli T, et al: Outcome of stroke with mild or rapidly improving symptoms. Stroke 2007;38:2531-2535.
8.
Smith EE, Fonarow GC, Reeves MJ, et al: Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from Get With The Guidelines-Stroke. Stroke 2011;42:3110-3115.
9.
Rajajee V, Kidwell C, Starkman S, et al: Early MRI and outcomes of untreated patients with mild or improving ischemic stroke. Neurology 2006;67:980-984.
10.
Kim JT, Park MS, Chang J, Lee JS, Choi KH, Cho KH: Proximal arterial occlusion in acute ischemic stroke with low NIHSS scores should not be considered as mild stroke. PLoS One 2013;8:e70996.
11.
Urra X, Ariño H, Llull L, et al: The outcome of patients with mild stroke improves after treatment with systemic thrombolysis. PLoS One 2013;8:e59420.
12.
Strbian D, Piironen K, Meretoja A, et al; Helsinki Stroke Thrombolysis Registry Group: Intravenous thrombolysis for acute ischemic stroke patients presenting with mild symptoms. Int J Stroke 2013;8:293-299.
13.
Köhrmann M, Nowe T, Huttner HB, et al: Safety and outcome after thrombolysis in stroke patients with mild symptoms. Cerebrovasc Dis 2009;27:160-166.
14.
Baumann CR, Baumgartner RW, Gandjour J, von Budingen HC, Siegel AM, Georgiadis D: Good outcomes in ischemic stroke patients treated with intravenous thrombolysis despite regressing neurological symptoms. Stroke 2006;37:1332-1333.
15.
Pantoni L, Fierini F, Poggesi A: Thrombolysis in acute stroke patients with cerebral small vessel disease. Cerebrovasc Dis 2014;37:5-13.
16.
Selim MH, Molina CA: Management of acute stroke patients with rapidly resolving deficits and persistent vascular occlusion: a real clinical equipoise. Stroke 2010;41:3007-3008.
17.
Novakovic RL, Toth G, Narayanan S, Zaidat OO: Retrievable stents, ‘stentrievers,' for endovascular acute ischemic stroke therapy. Neurology 2012;79:S148-S157.
18.
Broderick JP, Palesch YY, Demchuk AM, et al: Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 2013;368:893-903.
19.
Abilleira S, Cardona P, Ribó M, et al: Outcomes of a contemporary cohort of 536 consecutive patients with acute ischemic stroke treated with endovascular therapy. Stroke 2014;45:1046-1052.
20.
Tan IY, Demchuk AM, Hopyan J, et al: CT angiography clot burden score and collateral score: correlation with clinical and radiologic outcomes in acute middle cerebral artery infarct. AJNR Am J Neuroradiol 2009;30:525-531.
21.
Zaidi SF, Aghaebrahim A, Urra X, et al: Final infarct volume is a stronger predictor of outcome than recanalization in patients with proximal middle cerebral artery occlusion treated with endovascular therapy. Stroke 2012;43:3238-3244.
22.
Molina CA, Alexandrov AV, Demchuk AM, Saqqur M, Uchino K, Alvarez-Sabín J: Improving the predictive accuracy of recanalization on stroke outcome in patients treated with tissue plasminogen activator. Stroke 2004;35:151-156.
23.
Rha JH, Saver JL: The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke 2007;38:967-973.
24.
Ribo M, Flores A, Rubiera M, et al: Extending the time window for endovascular procedures according to collateral pial circulation. Stroke 2011;42:3465-3469.
25.
Rangaraju S, Owada K, Noorian AR, et al: Comparison of final infarct volumes in patients who received endovascular therapy or intravenous thrombolysis for acute intracranial large-vessel occlusions. JAMA Neurol 2013;70:831-836.
26.
Molina CA, Chamorro A, Rovira A, et al: REVASCAT: a randomized trial of revascularization with SOLITAIRE FR® device vs. best medical therapy in the treatment of acute stroke due to anterior circulation large vessel occlusion presenting within eight-hours of symptom onset. Int J Stroke 2013, DOI: 10.1111/ijs.12157.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.